Dalal Street Blogs provides information for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.
CAUTION: Dalal Street Blogs publishes market news and educational content only. We do not promote, recommend or endorse any stock, and nothing here is a solicitation to buy or sell securities. Please consult a SEBI-registered adviser before investing.
Market News

Ajanta Pharma Q2 Results: Profit Up 49%, Revenue Rises 33% (Oct 30, 2026)

3953
By Dalal Street Blogs EditorialUpdated 3 min read

Ajanta Pharma Q2 results came out in the middle of Friday’s session on October 30, and the numbers were the kind the market likes: revenue from operations up 33% year-on-year to ₹1,794 crore and profit after tax up 49% to ₹388 crore, according to the company’s board meeting outcome and press release. The stock responded. CNBC-TV18 reported the shares trading 2.67% higher at ₹3,552.10 after the announcement.

In this article
  1. Ajanta Pharma Q2 results: the headline numbers
  2. Where the growth came from
  3. The half-year picture
  4. What we would watch

Ajanta Pharma Q2 results: the headline numbers

Revenue for the September quarter was ₹1,794 crore against ₹1,354 crore a year earlier. Net profit of ₹388 crore compares with ₹260 crore, and the PAT margin (profit after tax as a share of revenue) moved up to 22% from 19%, per the investor presentation in the same filing. Basic earnings per share came in at ₹31.07 against ₹20.83.

The operating line is where the jump really shows. EBITDA (earnings before interest, tax, depreciation and amortisation) was ₹543 crore, a 30% margin. Last year’s reported EBITDA was ₹328 crore at 24%, but that quarter carried a forex mark-to-market loss. Strip it out and the company puts last year’s adjusted figure at ₹369 crore, or 27% of revenue. So the like-for-like growth is 47%, not the 66% the raw numbers suggest. We think the adjusted comparison is the fairer one.

Gross margin also widened to 79% from 77%, which helped. Sequentially, revenue was up from ₹1,626 crore in the June quarter and profit from ₹334 crore.

Where the growth came from

Every market grew, but not evenly. The company’s segment table shows:

  • India branded generics: ₹504 crore, up 16% from ₹432 crore.
  • Asia branded generics: ₹366 crore, up 18% from ₹310 crore.
  • Africa branded generics: ₹312 crore, up 41% from ₹221 crore.
  • US generics: ₹484 crore, up 41% from ₹344 crore.
  • Africa institutional business: ₹116 crore, against ₹32 crore a year ago.

The US and Africa did the heavy lifting this quarter. The Africa institution line is small and tends to be lumpy, since it depends on tender supplies, so we would not extrapolate a near fourfold jump. For India, the company cited IQVIA data for the twelve months to September 2026 showing its branded generics growing 17% against 13% for the overall Indian pharma market. It grew faster than the market in ophthalmology, dermatology and pain management, but slower in cardiology (13% against 17%), which management attributed to an anomaly in IQVIA’s working, saying its internal numbers are on par.

The half-year picture

For April to September, revenue rose 29% to ₹3,420 crore and profit rose 40% to ₹722 crore. Adjusted EBITDA for the half was ₹997 crore, up 34%. In the US pipeline, the company received four ANDA (abbreviated new drug application) approvals in the half, launched three products and filed one.

What we would watch

A 30% EBITDA margin is a high bar to hold, and a chunk of this quarter’s gain came from the two fastest-moving lines, US generics and Africa. The test over the next couple of quarters is whether India branded growth stays ahead of the market and whether US launches keep coming. Our Sun Pharma Q2 results piece from the same day gives a useful contrast within the sector.

If you want to read a results filing like this one yourself, start with our guide on how to analyse quarterly results, and this explainer on year-on-year versus quarter-on-quarter growth covers the comparisons used above.

Disclaimer: This article is for information only and is not investment advice. Please consult a SEBI-registered adviser before making investment decisions.

Leave a Reply

Join the conversation

Commenting is open to registered readers. Sign up with just your email — no password needed, and it takes under a minute.

Sign up to comment Log in